IsoPic™ uses biomechanical characteristics to capture the CTCs from the blood and does not rely on conventional biomarkers that often miss some of the rare and unpredictable cancer cells. The analysis of blood to find CTCs can be performed on apparently healthy people for early screening for cancer, and on those already afflicted by symptoms of cancer to potentially guide their treatment.
iCellate can with high sensitivity find the rare CTCs in the blood. The instrument IsoPic™ can find 90% of the CTCs in spiked tests with breast cancer, connective tissue cancer and cervical cancer cells.
The CTC’s genetic information can potentially provide an excellent tool for diagnosis, monitoring disease progression, predicting response to selected drugs and identify therapy-resistant cancer at early stage. Following CTCs enrichment and isolation, Next Generation Sequencing (NGS) analysis is applied for deep investigation of the CTC’s genetic makeup at the single cell level. This information enables clinical decision-making based on the few available cancer cells isolated by iCellate’s workflow. This approach may therefore help to provide broad access to personalized cancer medicine in the near future to all patients in a comprehensive, sensitive, fast and cost effective manner.